Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DANAHER CORPORATION

(DHR)
  Report
Delayed Nyse  -  01:01 2022-11-25 pm EST
267.04 USD   +1.40%
11/22Danaher to Present at Evercore ISI HealthCONx Conference
PR
11/16Insider Sell: Danaher
MT
11/15Cepheid Launches Multiplex Vaginal Panel (MVP) to Support More Accurate Women's Health Diagnosis in U.S.
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher Seeks M&A

09/15/2022 | 12:00pm EST

Danaher Corporation (NYSE:DHR) is seeking M&A. Rainer Blair said, "Well, I'll tell you, we -- first of all, I have to come back to the portfolio that we have. The EAS announcement is 12 hours or so -- just about 24 hours or so old, and it's going to take us to the end of next year really to complete that transaction. But having said that, as you rightly point out, we are very active in the field of M&A. Our funnels are as full as ever, and we will continue with our strategy to look at the white spaces of scale, always focusing on strategy and market first, then identifying the company and then ultimately ensuring that the business case works.

And if all those 3 turn green, as we say in DBS, then we'll pull the trigger. And we're currently in an environment in which we have historically performed very well from an M&A perspective. In times of dislocation, the number of opportunities increase, and we have several assets today in our portfolio.

SCIEX comes to mind of scale, and there are others that we precisely were able to acquire in this kind of time period. So expect us to continue to prioritize our capital deployment towards M&A, and that will happen at all scale levels from large to small".


ę S&P Capital IQ 2022
All news about DANAHER CORPORATION
11/22Danaher to Present at Evercore ISI HealthCONx Conference
PR
11/16Insider Sell: Danaher
MT
11/15Cepheid Launches Multiplex Vaginal Panel (MVP) to Support More Accurate Women's Health ..
PR
11/14Insider Sell: Danaher
MT
11/14Insider Sell: Danaher
MT
11/10Danaher Launches Beacon Initiative and Its First Partnership Focused on Gene Therapy In..
PR
11/10Danaher Corporation Enters Into Strategic Partnership with Duke University
CI
10/28What will the Fed do?
MS
10/28Analyst recommendations: Amazon, Apple, Caterpillar, Intel, Mast..
MS
10/25Earnings reports bonanza
MS
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Financials (USD)
Sales 2022 30 781 M - -
Net income 2022 6 466 M - -
Net Debt 2022 12 041 M - -
P/E ratio 2022 30,7x
Yield 2022 0,38%
Capitalization 194 B 194 B -
EV / Sales 2022 6,71x
EV / Sales 2023 6,49x
Nbr of Employees 79 000
Free-Float 74,6%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 267,04 $
Average target price 304,63 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose-Carlos GutiÚrrez-Ramos Chief Science Officer & Senior Vice President
Sadik Kassim Chief Technology Officer
Sector and Competitors